Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I understand the Trader you are!! Your post just need ignored from those that do not. Buckle up mofo, shit gonna get real this next month!!
Ignore this Poster folks. Wants as many cheapies as possible for the big run that will be here VERY SOON! Flipper flips, wants cheaper and repeat.
Tic Toc Tic Toc!! Hope everyone is buying these CHEAPIES.
BOOOM!
Yep Yep! Hope all are buying these CHEAPIES now
Thank God for Beer and Liquor!
Timing101, All in your name my friend!! Great job with your DD! Not much longer!
LOL! IF? I already knew that, but that will NOT BE all. GLTU
Well, you move on then. THIS MERGER WILL CLOSE and it will not be long, just a little patience. Remember, not long ago BioClonetics mentioned in their Investment paper that they would have Pharma Companies ready to get it going once done.
THINK ABOUT THAT HARD
I too have made calls, buying all I can. These guys are very well known and this MERGER WILL BE COMPLETED!! This is the time to load what you can, cause the clock is ticking.
Covid is going to be a big focus as well for them. Some strains of HIV have been found in Covid in my dd. Big money maker coming here! Good day
Shhhhhhhhhhhh! Only a matter of time for the Gamechanger!!
Boooyaaaa! Great Find!! Updated dates, CEO
Betting there is. Shall c, still digging. But, I think there IS a CEO in JPEX now
Was digging last night, looking like a merger happening
Yes Sir, just patiently waiting to add a large chunk as well.
The Gates Foundation knows who Harry is, and i am sure they know BioClonetics as well
Called Connections, called who knows who and what have you DEVELOPED?!
BIG my friend, especially from all we have found in our DD!! When it really runs, lol!! Gonna get nuts
moolamoola Monday, 09/14/20 05:41:05 PM
Re: BluE33 post# 20181 0
Post # 20183 of 23429
HIV treatment is great...but yes Im curious what else surprise they may have for us, yes we are in the midst of a virus war right now, anything that can improve our immunue system...never know
"BioClonetics said that because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, the company has been asked by the National Science Foundation @NSF to submit a funding application for development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health."
DD for ALL! I have found so much that Todays is enough to Convince ME, the time to truly fight HIV and Covid is upon us with this Merger of Enzolytics Inc and BioClonetics. PATENTS, Sector Connections and Ties, TONS Of EXPERIENCE, on and on!
BioClonetics said that because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, the company has been asked by the National Science Foundation @NSF to submit a funding application for development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health.
Remember, this was months ago. Betting they got PLENTY TO TELL IN THE NEAR TERM.
our Duke PHD https://surgery.duke.edu/news/david-montefiori-phd-receives-326-million-grant-gates-foundation-hiv-vaccine-research
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158370680
LET THIS SINK IN: BioClonetics FINAL stage of development of a parent monoclonal antibody ("mAbs") (designated as Clone 3), which is non-toxic & has shown in initial in vitro testing 2 B Effective against More than 95% of ALL Strains & viral subtypes of HIV-1 against which it's been tested
BioClonetics INVITED by the National Science Foundation (NSF) 2 submit an application 4 funding 4 development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary #Technology. Such application to the NSF & a corresponding application to the NIH R NOW PENDING
The Company is also looking to expand its Medical Advisory board with individuals that have direct experience taking medical products through the regulatory process and bringing them to market. Betting we do NOT have to look far for these Additions.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158391702
Okay, Now some serious ties: Easier to post pages so I do not run out of room, lmao!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402294
More on Genscript: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402747
https://www.linkedin.com/in/craigvomlehn/ Click Interest, Then Companies!!!
ALSO http://bioclonetics.com/who-we-are.html
Key Figure is Tomasz Zastawny, Chief Clinical Operations Officer, DSc, Ph.D.
Vice President, Head of Clinical Operations at Epizyme
https://www.linkedin.com/company/epizyme/about/ HUGE!!!
$EPZY NASDAQ $13.26
Hello, my name is Rich Krebs. I'm currently a Senior Principal Scientist with Zoetis. We are an animal health company who recently introduced the first animal health monoclonal antibody treatment. I'm a believer in the concept and I believe your company is able to accomplish it's goals.
Richard Krebs
Senior Principal Scientist in R&D for an animal health company.
INVESTOR IN BioClonetics!!!
Look up Zoetis!!
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. Wikipedia
Stock price: ZTS (NYSE) $160.87 +0.40 (+0.25%)
Sep 18, 4:05 PM EDT - Disclaimer THIS GUY INVESTED IN BIOCLONETICS FOLKS! U THINK THIS COMPANY KNOWS WHO BIOCLONETICS IS NOW??!!! LOL! I DO!
1 MORE BIGGIE DD and TIES.
THE BUZZ ABOUT BIOCLONETICS IMMUNOTHERAPEUTICS
Despite effective anti-HIV retrovirals, clearance of HIV-1 remains a critical global health issue. We are excited to be part of your strong interdisciplinary team and you have our full support for successful advancement of your technology.
Magdalena Leszczyniecka, Ph.D., MBA
CEO and Present, STC Biologics, Inc.
DD HER and Her Company!! Started at Novartis
Pharmaceuticals
https://stcbiologics.com/
STC was founded in 2009 and its team brings expertise in biologics drug development and global regulatory approvals from Genentech, Novartis, Shire, EMD Serono, Lonza, Alexion and Merrimack.
She gained start up experience prior to STC working for venture capital firms: Flagship Ventures and Atlas Ventures. She has led the development of MM-121 and anti-HER3 antibody programs at Merrimack Pharmaceuticals.
Here is more from her: https://www.rihl.in/hiv-curable-now-with-monoclonal-antibodies/
This is old, but once again, Shows People knowing People and Companies
Page 19 and 73
https://conshouston.esteri.it/resource/2011/11/42712_f_cons57RaccoltainterventiConferenzadeiRicercatori2010.pdf
Lastly, old but... you get the point!!
https://www.digitalnicheagency.com/ BUT...listed on the page with big names just looks nice as shit folks!!
CHEERS TO THIS MERGER!! GAMECHANGER!
Nice job! More connections. Seems many know who Enzolytics and BioClonetics are. Now, they are merging with their solutions to help the world and .....investors!
This guy has Enzolystics on his front page just under his business, Into : https://www.facebook.com/guile.go
No DM here, as I let it expire. Twitter Crabbermike. GLTU and be safe out there! Waters down there are crazy with those currents. Take care
"About 2 months ago I sent Harry’s info and contact to the Gates Foundation. They told me they were aware of who they are. I texted Harry about it.....haven’t heard any more, but was probably moving forward way before that...."
That in itself is absolutely HUGE DD Great job, and you probably do not know how great, lol!
DD for ALL! I have found so much that Todays is enough to Convince ME, the time to truly fight HIV and Covid is upon us with this Merger of Enzolytics Inc and BioClonetics. PATENTS, Sector Connections and Ties, TONS Of EXPERIENCE, on and on!
I also have a tad more DD, but will reveal AFTER I buy more, lol Oh, I am Crabbermike on Twitter for those that have asked.
BioClonetics said that because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, the company has been asked by the National Science Foundation @NSF to submit a funding application for development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health.
Remember, this was months ago. Betting they got PLENTY TO TELL IN THE NEAR TERM.
our Duke PHD https://surgery.duke.edu/news/david-montefiori-phd-receives-326-million-grant-gates-foundation-hiv-vaccine-research
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158370680
LET THIS SINK IN: BioClonetics FINAL stage of development of a parent monoclonal antibody ("mAbs") (designated as Clone 3), which is non-toxic & has shown in initial in vitro testing 2 B Effective against More than 95% of ALL Strains & viral subtypes of HIV-1 against which it's been tested
BioClonetics INVITED by the National Science Foundation (NSF) 2 submit an application 4 funding 4 development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary #Technology. Such application to the NSF & a corresponding application to the NIH R NOW PENDING
The Company is also looking to expand its Medical Advisory board with individuals that have direct experience taking medical products through the regulatory process and bringing them to market. Betting we do NOT have to look far for these Additions.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158391702
Okay, Now some serious ties: Easier to post pages so I do not run out of room, lmao!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402294
More on Genscript: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402747
https://www.linkedin.com/in/craigvomlehn/ Click Interest, Then Companies!!!
ALSO http://bioclonetics.com/who-we-are.html
Key Figure is Tomasz Zastawny, Chief Clinical Operations Officer, DSc, Ph.D.
Vice President, Head of Clinical Operations at Epizyme
https://www.linkedin.com/company/epizyme/about/ HUGE!!!
$EPZY NASDAQ $13.26
Hello, my name is Rich Krebs. I'm currently a Senior Principal Scientist with Zoetis. We are an animal health company who recently introduced the first animal health monoclonal antibody treatment. I'm a believer in the concept and I believe your company is able to accomplish it's goals.
Richard Krebs
Senior Principal Scientist in R&D for an animal health company.
INVESTOR IN BioClonetics!!!
Look up Zoetis!!
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. Wikipedia
Stock price: ZTS (NYSE) $160.87 +0.40 (+0.25%)
Sep 18, 4:05 PM EDT - Disclaimer THIS GUY INVESTED IN BIOCLONETICS FOLKS! U THINK THIS COMPANY KNOWS WHO BIOCLONETICS IS NOW??!!! LOL! I DO!
1 MORE BIGGIE DD and TIES.
THE BUZZ ABOUT BIOCLONETICS IMMUNOTHERAPEUTICS
Despite effective anti-HIV retrovirals, clearance of HIV-1 remains a critical global health issue. We are excited to be part of your strong interdisciplinary team and you have our full support for successful advancement of your technology.
Magdalena Leszczyniecka, Ph.D., MBA
CEO and Present, STC Biologics, Inc.
DD HER and Her Company!! Started at Novartis
Pharmaceuticals
https://stcbiologics.com/
STC was founded in 2009 and its team brings expertise in biologics drug development and global regulatory approvals from Genentech, Novartis, Shire, EMD Serono, Lonza, Alexion and Merrimack.
She gained start up experience prior to STC working for venture capital firms: Flagship Ventures and Atlas Ventures. She has led the development of MM-121 and anti-HER3 antibody programs at Merrimack Pharmaceuticals.
Here is more from her: https://www.rihl.in/hiv-curable-now-with-monoclonal-antibodies/
This is old, but once again, Shows People knowing People and Companies
Page 19 and 73
https://conshouston.esteri.it/resource/2011/11/42712_f_cons57RaccoltainterventiConferenzadeiRicercatori2010.pdf
Lastly, old but... you get the point!!
https://www.digitalnicheagency.com/ BUT...listed on the page with big names just looks nice as shit folks!!
CHEERS TO THIS MERGER!! GAMECHANGER!
Monster blocks indeed! Fridays buys tell the tale of where this stock is going! 1,2,3 tick flippers thought under .005, then BOOM!!! EVERYTHING GOT BOUGHT UP FROM OUTSIDE MONEY!!!
Todays DD Alone. I have found so much that Todays is enough to Convince ME, the time to truly fight HIV and Covid is upon us with this Merger of Enzolytics Inc and BioClonetics. PATENTS, Sector Connections and Ties, TONS Of EXPERIENCE, on and on!
BioClonetics said that because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, the company has been asked by the National Science Foundation @NSF to submit a funding application for development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health.
Remember, this was months ago. Betting they got PLENTY TO TELL IN THE NEAR TERM.
our Duke PHD https://surgery.duke.edu/news/david-montefiori-phd-receives-326-million-grant-gates-foundation-hiv-vaccine-research
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158370680
LET THIS SINK IN: BioClonetics FINAL stage of development of a parent monoclonal antibody ("mAbs") (designated as Clone 3), which is non-toxic & has shown in initial in vitro testing 2 B Effective against More than 95% of ALL Strains & viral subtypes of HIV-1 against which it's been tested
BioClonetics INVITED by the National Science Foundation (NSF) 2 submit an application 4 funding 4 development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary #Technology. Such application to the NSF & a corresponding application to the NIH R NOW PENDING
The Company is also looking to expand its medical advisory board with individuals that have direct experience taking medical products through the regulatory process and bringing them to market.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158391702
Okay, Now some serious ties: Easier to post pages so I do not run out of room, lmao!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402294
More on Genscript: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402747
https://www.linkedin.com/in/craigvomlehn/ Click Interest, Then Companies!!!
ALSO http://bioclonetics.com/who-we-are.html
Key Figure is Tomasz Zastawny, Chief Clinical Operations Officer, DSc, Ph.D.
Vice President, Head of Clinical Operations at Epizyme
https://www.linkedin.com/company/epizyme/about/ HUGE!!!
$EPZY NASDAQ $13.26
Hello, my name is Rich Krebs. I'm currently a Senior Principal Scientist with Zoetis. We are an animal health company who recently introduced the first animal health monoclonal antibody treatment. I'm a believer in the concept and I believe your company is able to accomplish it's goals.
Richard Krebs
Senior Principal Scientist in R&D for an animal health company.
INVESTOR IN BioClonetics!!!
Look up Zoetis!!
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. Wikipedia
Stock price: ZTS (NYSE) $160.87 +0.40 (+0.25%)
Sep 18, 4:05 PM EDT - Disclaimer
1 MORE BIGGIE DD and TIES.
THE BUZZ ABOUT BIOCLONETICS IMMUNOTHERAPEUTICS
Despite effective anti-HIV retrovirals, clearance of HIV-1 remains a critical global health issue. We are excited to be part of your strong interdisciplinary team and you have our full support for successful advancement of your technology.
Magdalena Leszczyniecka, Ph.D., MBA
CEO and Present, STC Biologics, Inc.
DD HER and Her Company!! Started at Novartis
Pharmaceuticals
https://stcbiologics.com/
STC was founded in 2009 and its team brings expertise in biologics drug development and global regulatory approvals from Genentech, Novartis, Shire, EMD Serono, Lonza, Alexion and Merrimack.
She gained start up experience prior to STC working for venture capital firms: Flagship Ventures and Atlas Ventures. She has led the development of MM-121 and anti-HER3 antibody programs at Merrimack Pharmaceuticals.
This is old, but once again, Shows People knowing People and Companies
Page 19 and 73
https://conshouston.esteri.it/resource/2011/11/42712_f_cons57RaccoltainterventiConferenzadeiRicercatori2010.pdf
Lastly, old but... you get the point!!
https://www.digitalnicheagency.com/ BUT...listed on the page with big names just looks nice as shit folks!!
CHEERS TO THIS MERGER!! GAMECHANGER!
1 MORE BIGGIE DD and TIES.
THE BUZZ ABOUT BIOCLONETICS IMMUNOTHERAPEUTICS
Despite effective anti-HIV retrovirals, clearance of HIV-1 remains a critical global health issue. We are excited to be part of your strong interdisciplinary team and you have our full support for successful advancement of your technology.
Magdalena Leszczyniecka, Ph.D., MBA
CEO and Present, STC Biologics, Inc.
DD HER and Her Company!! Started at Novartis
Pharmaceuticals
https://stcbiologics.com/
STC was founded in 2009 and its team brings expertise in biologics drug development and global regulatory approvals from Genentech, Novartis, Shire, EMD Serono, Lonza, Alexion and Merrimack.
She gained start up experience prior to STC working for venture capital firms: Flagship Ventures and Atlas Ventures. She has led the development of MM-121 and anti-HER3 antibody programs at Merrimack Pharmaceuticals.
Agree. Enjoy the day. I will collect all I found and put in 1 post tonight sometime. Later
MORE DD!! Oh, who in the hell you keep argueing with? I got many on iggy, lmao!!
Hello, my name is Rich Krebs. I'm currently a Senior Principal Scientist with Zoetis. We are an animal health company who recently introduced the first animal health monoclonal antibody treatment. I'm a believer in the concept and I believe your company is able to accomplish it's goals.
Richard Krebs
Senior Principal Scientist in R&D for an animal health company.
INVESTOR IN BioClonetics!!!
Look up Zoetis!!
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. Wikipedia
Stock price: ZTS (NYSE) $160.87 +0.40 (+0.25%)
Sep 18, 4:05 PM EDT - Disclaimer
NICE! Thanks
https://www.linkedin.com/in/craigvomlehn/ Click Interest, Then Companies!!!
ALSO http://bioclonetics.com/who-we-are.html
Key Figure is Tomasz Zastawny, Chief Clinical Operations Officer, DSc, Ph.D.
Vice President, Head of Clinical Operations at Epizyme
https://www.linkedin.com/company/epizyme/about/ HUGE!!!
$EPZY NASDAQ $13.26
Great Job! This is old, but once again, Shows People knowing People and Companies
Page 19 and 73
https://conshouston.esteri.it/resource/2011/11/42712_f_cons57RaccoltainterventiConferenzadeiRicercatori2010.pdf
GenScript Biotech Corp. (Stock Code: 1548.HK), a leading global biotechnology company, today reported interim results for the six months ended June 30, 2020 and provided a corporate update. Revenue of the Group for the six months ended June 30, 2020 was approximately US$166.4 million, representing an increase of 36.5% from the same period in 2019. The external revenue for non-cell therapy business was approximately US$143.3 million, representing an increase of 41.6% from the same period of 2019. The adjusted profit of non-cell therapy business more than doubled. The revenue for cell therapy business was approximately US$23.1 million, representing an increase of 11.6% from the same period of 2019.
In the first half of 2020, the Group maintained strong momentum across all four business segments. Among others, life science CRO business delivered impressive results and saw fastest growth since IPO of the Company, with revenue increasing by 49.1%. Revenue from CDMO business (GenScript ProBio) increased by over 100% in the first half of 2020. Despite the COVID-19 outbreak, industrial synthetic biology business managed to grow faster than the industry average. In the cell therapy segment, the subsidiary Legend Biotech was listed on Nasdaq Global Market in June 2020 as China's first CAR-T stock, expecting to initiate a biologics license application (BLA) for its first CAR-T therapy ciltacabtagene autoleucel (cilta-cel) with US Food and Drug Administration (FDA) by the end of 2020.
In terms of results of the four business segments, revenue from life science services and products amounted to approximately US$115.0 million, representing an increase of 39.9% from the same period in 2019. The gross profit was approximately US$78.0 million, representing an increase of 49.1% from the same period in 2019. The gross profit margin increased from 63.6% for the same period last year to 67.8% this year. The adjusted operating profit of life science services and products (excluding share-based compensation expenses and central management expenses) was approximately US$41.6 million, representing an increase of 65.8%. Revenue growth was mainly attributable to the (i) successful commercial operation that focused on COVID-19 related products such as protein and antibody,
MORE MONSTER TIES FOR FOLKS THAT DIG LIKE ME:
Charles Cotropia, CEO and co-founder of BioClonetics Immunotherapeutics
"Our anti-HIV monoclonal antibody is one of only a few that target the HIV virus at a site that does not mutate. While other antibodies being examined have initial efficacy, most target a site that on the virus that changes with time. In other words, the virus structure changes so that the antibody is no longer effective. This ability of a virus to mutate is not new news — the flu virus and all others, do it every year. Otherwise there would be no need to re-engineer the flu virus each year."
Use of a monoclonal antibody to treat the HIV virus offers another unvoiced benefit.
Use of monoclonal antibodies would not require lifelong treatment but would be effective if administered for a limited time. And the antibody can be produced for pennies a dose. Thus, their impact on worldwide health could be remarkable.
Companies such as Genscript Labs, STC Biologics, Rapid Novor and Scripps Research have been most gracious in their willingness to work with us to move our technology forward.
DD Genscript labs folks. Holy shit! plus, look at some of the names:
Jon Stonehouse, a pharmaceutical executive for more than 20 years, has strong commercialization, financial transaction, business development and management expertise. He joined BioCryst as President and CEO in January 2007. NASDAQ LISTED! The transformation that has taken place since then has advanced BioCryst to a company with its first product revenue and approvals, pivotal clinical programs and a diverse clinical pipeline, as well as the financial flexibility to build an enduring, successful biopharmaceutical company. Before joining BioCryst, he served as Senior Vice President of Corporate Development at MERCK KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company, which culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe.
George Church
Dr. George Church, Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), co-author of 515 papers, 143 patent publications & the book "Regenesis". Dr. Church has developed methods used for the first genome sequence (1994) & million-fold cost reductions since (via fluor-NGS & nanopores), plus barcoding, DNA assembly from chips, genome editing, writing & recoding. He also co-initiated BRAIN Initiative (2011) & Genome Projects (GP-Read-1984, GP-Write-2016, PGP-2005: world's open-access personal precision medicine datasets); machine learning for protein engineering, tissue reprogramming, organoids, xeno-transplanation, in situ 3D DNA, RNA, protein imaging.
SOME OF THE LISTED COMPANIES WITH TIES Directly or Indirectly
BioCryst NASDAQ LISTED
Merck NYSE LISTED
GenScript LISTED IN HONG KONG WHO SPUN OFF NASDAQ LISTED LEGEND BioTECH $32
Read these pr's from just 1 of the Companies helping BioClonetics FORWARD! https://www.genscript.com/special/press-release
NOW, ADD IN WHAT Enzolytics HAS DEVELOPED!!
MONEY SHOT MY FRIEND!! MASSIVE DD
GOTTA SAY, I CAN NOT FIND A BETTER #STOCK TO BUY AND HOLD GOING INTO NEXT WEEK! 1 K FILING, 1 PR AND WE ARE PENNIESSSSSS! THEY ARE ALL COMING IN THE SHORT TERM, COUNT ON IT.
HAVE A GOOD WEEKEND FOLKS